Research Paper Volume 11, Issue 24 pp 12315—12327

β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson’s rats


Figure 4. Recombinant AAV-mediated β-arrestin2 knock-down (β-arrestin2-/-) in 6-OHDA-lesioned rats treated with L-dopa. (A) The whole process of the second part experimental design (n=56); (B) AAV-β-arrestin2 knock-down (β-arrestin2-/-) relative to GAPDH level in five groups by WB in the lesioned striatum (n = 4 for each group, total n=4*5=20); (C) AAV-β-arrestin2 knock-down (β-arrestin2-/-) in five groups by IHC in the lesioned striatum. Scale bar represents 100 um. @ P<0.0001, * p<0.05 vs LID + sh. EGFP group (n = 4 for each group, total 4*5=20, ANOVA followed by LSD post-hoc comparisons).